中金:創新藥板塊投資熱情高昂 下半年關注ESMO
中金髮布研報稱,2025年,流動性預期樂觀以及國內AI等技術突破等都導向以及創新藥爲代表的醫藥科技類資產更適合今年的投資環境。短期ASCO衆多臨牀數據披露,以及三生爲代表的大額BD落地,進一步證實中國創新藥開始具備國際化競爭力。下半年ESMO會議的召開,以及圍繞會議前後的數據披露與BD將對創新藥有較爲積極催化。受益於下遊創新藥板塊今年的積極表現,一二級新藥投融資環境改善,對以內需CRO和科研上遊爲代表的供應鏈體系有較爲積極的訂單改善邊際影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.